Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Myriad Genetics Inc
(NQ:
MYGN
)
17.99
-3.97 (-18.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,737,817
Open
20.04
Bid (Size)
17.18 (2)
Ask (Size)
17.98 (1)
Prev. Close
21.96
Today's Range
16.86 - 20.06
52wk Range
15.99 - 29.30
Shares Outstanding
90,900,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
November 01, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
November 01, 2024
Via
Benzinga
Performance
YTD
-5.32%
-5.32%
1 Month
-31.93%
-31.93%
3 Month
-30.38%
-30.38%
6 Month
-9.91%
-9.91%
1 Year
+5.70%
+5.70%
More News
Read More
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
November 01, 2024
Via
Benzinga
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Analyst Expectations For Myriad Genetics's Future
September 19, 2024
Via
Benzinga
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
August 13, 2024
Via
Benzinga
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
October 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
October 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
October 08, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
October 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
October 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
September 18, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
September 05, 2024
Via
Benzinga
Myriad Genetics to Host Investor Event on October 9, 2024
September 05, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
August 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
August 13, 2024
Via
Investor's Business Daily
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
August 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
July 31, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Avantor Stock Earns 84 RS Rating
July 30, 2024
Via
Investor's Business Daily
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
July 17, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
July 11, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
July 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.